This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Remibrutinib (Novartis oral BTK-selective covalent kinase inhibitor clinical candidate)
molecule
2 years ago ●
1 min read
February’s molecule, the Novartis factor B inhibitor LNP023, targets the serine protease factor B (FB), a key node in the complement system.…
molecule
2 years ago ●
1 min read
LMB763 (nidufexor) (Novartis (GNF) oral in vivo selective FXR partial agonist)
molecule
2 years ago ●
1 min read
ABBV-744 (AbbVie oral in vivo BD2 domain selective BET inhibitor)
molecule
2 years ago ●
1 min read
AG-881 (vorasidenib)Â (Agios oral brain penetrant allosteric mutant IDH1/2 dual inhibitor clinical candidate)
molecule
2 years ago ●
1 min read
FT-2102 (olutsidenib) (FORMA oral allosteric mutant-selective IDH1 inhibitor clinical candidate)
molecule
2 years ago ●
1 min read
Load More
